Latest progress
Recently, Salubris announced that its subsidiary Salubris Biotherapeutics, Inc. (hereinafter referred to as "SalubrisBio") self-developed broad-spectrum anti-tumor innovative biologic drug JK06 was approved to carry out Phase I clinical study after submitting CTA (European Clinical Trial Application).
JK06 independently developed by SalubrisBio is an innovative antibody drug conjugate targeting 5T4, which is intended to be developed as a broad-spectrum solid tumor therapy.
At present, it has been approved to carry out phase I clinical trial in some European countries. The Phase I clinical trial is an open-label, dose-escalation and expansion study to evaluate the safety, pharmacokinetics and preliminary efficacy of JK06.
Preclinical study data showed that JK06 has robust efficacy and a clean safety profile. If successfully developed and approved for market, it is expected to provide patients with a new option with greater development potential.
| Related information
5T4 is an oncofetal protein that is limited in expression in adult normal tissues, but overexpressed in a wide range of tumor types, including lung, breast, renal and genitourinary cancers, and is associated with a poor prognosis and more aggressive tumor progression.
5T4 upregulation is playing a major role in the cancer heterogeneity, aggressiveness and metastatic potential, therefore, it is one of the ideal targets in the field of tumor immunotherapy.
